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Introduction: L-lactate is a metabolite that is 
oxidized preferentially to glucose under conditions of 
high metabolic stress. The discovery and localization 
of the lactate receptor HCA1 in various brain regions 
suggests that lactate is additionally an important signaling 
molecule in the brain. Lactate is neuroprotective in various 
ischemia paradigms, reduces axonal injury in vitro and is 
avidly utilized by oligodendrocytes (OLs). The protective 
potential of L-lactate to reduce white matter (WM) injury 
in a mouse stroke model was investigated.
Methods: A single dose of L-lactate (250mgkg-1) or 
vehicle was administered intraperitoneally shortly before 
or following a transient 60-minute middle cerebral artery 
occlusion (MCAO) in mice. Integrity of WM was assessed 
using histological and immunohistochemical methods at 24 
hours and 7 days of reperfusion. Modulation of the lactate 
receptor HCA1 on WM OLs with or without L-lactate 
treatment was investigated by immunofluorescence.
Results: Treatment with L-lactate resulted in improved 
histological staining in affected WM, reduced ischemia-
induced OL loss and attenuated apoptotic signaling in OLs 
compared to vehicle at acute and subacute stages. Further 
to previously reported neuronal expression, HCA1 was 
found to be localized on WM OLs. Ischemia elicited an 
increase in HCA1 fluorescence expression on WM OLs, 
particularly in regions proximal to the occluded artery. 
HCA1 expression was further amplified by exogenous 
L-lactate at acute and subacute stages.
Conclusion: These data suggest that protection by 
L-lactate extends beyond gray matter in a clinically relevant 
rodent focal ischemia model. Modulation of the HCA1 
receptor on OLs presents a novel role for lactate signaling 
in WM which could be involved in OL injury and survival 
pathways. 
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Introduction: Absence epilepsy is a paediatric 
neurological condition characterised by recurrent 
generalised non-convulsive seizures. Currently, 
pharmacological intervention for the management 
of epilepsy aims to acieve total seizure control, and is 
sometimes successful. However, at present, there exists 
no medication to prevent epileptogenesis from occurring 
in the first place. Research has shown various key players 
in the regulation of neuronal hyperexcitability. Some 
highlighted neurotransmitters include monoamines, 
serotonin, as well as endocannabinoids. Phyto- and 
synthetic-cannabinoids (CB), and endocannabinoids have 
shown to have anti-epileptic effects; however, their effects 
on comorbid memory impairment, anxiety and depression 
are not known.
Methods: The aim of this study is to investigate the effect 
of endocannabinoid neuronal systems on seizure control, 
development of depression and anxiety in the Genetic 
Absence Epilepsy Rat from Strasbourg (GAERS) and in 
their Non Epileptic Control (NEC) rats. EEG recording 
and behavioral tests such as hole board, elevated plus maze 
and forced swimming test will be used to evaluate the effect 
of cannabinoid compounds.
Results: This has been carried out by using low doses of 
the cannabinoid agonist WIN 55, 212-2s (WIN) at 2mg/kg 
IP, compared to its vehicle. The use of drugs blocking the 
cannabinoid receptor CB1-antagonist AM251 (1mg/kg IP) 
will also be investigated to verify whether WIN effects are 
mediated by this receptor.
Conclusion: We will provide evidence for CB 
dysfunction in this disease and identify potential targets that 
may, in the medium term, lead to novel anti-absence drugs. 
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Introduction: Seizures remain a common important 
neurological presentation to all acute hospitals worldwide. 
The National Audit of Seizure Management in Hospitals 
(NASH) collected data on about 9000 patients presenting 
with seizures to over 150 hospitals in the UK, identifying 
an unacceptable variation in the quality of care. The 
EuropeaN Audit of Seizure Management in Hospitals 
(EuroNASH) is currently being undertaken in a number of 
European countries, including Malta.
Methods: The aim of EuroNASH is to establish the 
first European benchmark for the management of seizures. 
Anonymous data was collected retrospectively on acute 
management, prior care and onward care for 50 patients 
who presented to Mater Dei with seizures between August 
2016 and 2017, by reviewing the clinical notes. While the 
results from EuroNASH are yet to be published, we can 
compare local data with that from NASH.
Results: The median age was 47, and 60% were male, 
(NASH: median age 44, 57% male). 54% of Maltese 
patients and 61% of NASH patients had a known prior 
diagnosis of epilepsy (p=0.33). Of these, 63% of Maltese 
patients were seen by an epilepsy specialist during the 
previous year compared to only 37% of patients in the 
UK (p< 0.05). Ninety-eight percent (98%) of our patients 
were reviewed by a specialist during admission or got early 
referral, compared to 53.9% of NASH patients (p<0.05). 
Nighty-four percent (94%) of Maltese patients were seen by 
a doctor within 4 hours of presentation to the emergency 
